 | | | | | | | | | | | | | | |
 |
[
admission conditions
]
[ ] [ ]
|
Advanced Master in Industrial Pharmacy
 |
Or
|
Th
|
Pr
|
Au
| Credits
|
A single year
|
Compulsory courses
|
|
PHIN2004-1
|
Active substances
|
|
|
|
| 6
|
| |
- Substances issues de recherches pharmacochimiques, part a - Bernard Pirotte
| | 10
| -
| -
| |
| |
- Substances issues de recherches pharmacochimiques, part b - Françoise Dufrasne
| | 5
| -
| -
| |
| |
- Substances issues des biotechnologies - Jean-Paul Dehaye
| | 15
| -
| -
| |
| |
- Substances d'origine naturelle, part a - Joëlle Quetin-Leclercq
| | 5
| -
| -
| |
| |
- Substances d'origine naturelle, part b - Pierre Duez
| | 5
| -
| -
| |
| |
- Produits radiopharmaceutiques - Ghanem Ghanem
| | 10
| -
| -
| |
|
PHIN2008-2
|
Clinical viewpoints
|
|
|
|
| 6
|
| |
- Métabolisme des médicaments et paramètres pharmacocinétiques - Roger Verbeek
| | 20
| -
| -
| |
| |
- Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - André Scheen
| | 15
| -
| -
| |
| |
- Information et pharmacovigilance - Raphaël Denooz
| | 10
| -
| -
| |
|
PHIN2013-2
|
Quality assurance and pharmaceutical management
|
|
|
|
| 7
|
| |
- Principles of pharmaceutical management - Jean-Michel Van Der Hofstadt
| | 10
| -
| -
| |
| |
- Quality assurance, part a : basic concepts and quality assurance organisation - Jean Scouvart
| | 20
| -
| -
| |
| |
- Quality assurance, part b : Analytical technology of procedures and risk analysis - Xavier Marcelis
| | 7,5
| -
| -
| |
| |
- English applied to the pharmaceutical industry - Didier Lambert, Nevin Serbest
| | 20
| -
| -
| |
| |
- Pharmaceutical marketing - Vincent Bierlaire
| | 7,5
| -
| -
| |
|
PHIN2022-1
|
Industrial pharmaceutical technology
|
|
|
|
| 8
|
| |
- Microbiologie pharmaceutique industrielle - Véronique Fontaine
| | 15
| -
| -
| |
| |
- Préformulation et sélection des formes galéniques - Karim Amighi
| | 15
| -
| -
| |
| |
- Production industrielle des formes galéniques - Brigitte Evrard
| | 15
| -
| -
| |
| |
- Génie pharmaceutique - Jean Gillard
| | 15
| -
| -
| |
| |
- Aspects industriels du développement technologique y compris le conditionnement - Laurence Denis
| | 10
| -
| -
| |
|
PHIN2023-1
|
Drug analysis
|
|
|
|
| 7
|
| |
- Analytical methods and pharmaceutical and biopharmaceutical control, part a - Jean-Michel Kauffman, Pierre Van Antwerpen
| | 10
| -
| -
| |
| |
- Analytical methods and pharmaceutical and biopharmaceutical control, part b - Marianne Fillet
| | 10
| -
| -
| |
| |
- Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment - Philippe Hubert, Eric Rozet
| | 15
| -
| -
| |
| |
- Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology - Philippe Hubert, Eric Ziemons
| | 5
| -
| -
| |
| |
- Statistical methods applied to the pharmaceutical industry - Bernadette Govaerts
| | 15
| -
| -
| |
| |
- Experimental planning and "quality by design" - Bruno Boulanger
| | 10
| -
| -
| |
|
PHIN2029-2
|
Regulation and the medical-social environment
|
|
|
|
| 8
|
| |
- Economic aspects of drug development - Dominique Martin
| | 10
| -
| -
| |
| |
- Legislation and procedures applied to pharmaceutical industry, part a : legislation - Catherine Druez
| | 10
| 5
| -
| |
| |
- Legislation and procedures applied to pharmaceutical industry, part b : patents and protection - Patrick Di Stefano
| | 5
| -
| -
| |
| |
- Macroeconomic environment and pharmaco-economics - Pierre Duez
| | 10
| -
| -
| |
| |
- CTD File (Common Technical Document) - Jean-Antoine De Muylder
| | 15
| -
| -
| |
| |
- Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files - Sonia Beken
| | 15
| -
| -
| |
| |
- Regulations of preclinical and clinical studies, part b : clinical studies - A Lenaers
| | 5
| -
| -
| |
| |
- Regulations of preclinical and clinical studies, part c : pediatric studies - Daniel Brasseur
| | 2,5
| -
| -
| |
| |
- Specific regulatory issues, part a : medicine and herbal dietary supplement - Monique Tits
| | 5
| -
| -
| |
| |
- Specific regulatory issues, part b : Preformulation and galenical development documentation - Francis Vanderbist
| | 5
| -
| -
| |
|
PHIN2032-1
|
Visits and seminars organised in the pharmaceutical industry - Collégialité - [77,5h Vis.]
|
| -
| -
| [+]
| 3
|
|
MTFE2000-1
|
Final work - Collégialité
|
| -
| -
| -
| 15
|
